Extensively revised, comprehensive content from leading global contributors ensures that Hematology, 8th Edition, remains your #1 choice for expert guidance in all areas of this rapidly advancing subspecialty. This edition reflects the numerous advances that are redefining the field and dramatically influencing new approaches to diagnosis, treatment, and outcomes. Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy—covering virtually all aspects of hematology in one definitive resource.
Covers all hematologic disorders, including comprehensive discussions of hematologic malignancies, individualized patient care, cell-based therapies, transplantation, transfusion medicine, hemostasis, thrombosis, and consultative hematology—in one convenient volume.
Provides state-of-the-art guidance from global experts at the forefront of the latest research and clinical practice.
Provides extensive updates throughout on basic science research, advances in molecular diagnostics, new drugs, immunotherapies, personalized medicine, laboratory medicine, transfusion medicine, stem cell transplantation, and clinical treatment for all hematologic malignancies and non-malignancies
Contains new chapters on gene editing; the impact of mitochondria on hematopoiesis; myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes; immunotherapy and management of its toxicities; transfusion medicine in sickle cell disease; principles of radiation therapy; and COVID-19, including complications of vaccination and its impact on the hematologic system.
Discusses many new advances in the field, including details and the future of gene therapy for hemophilia, gene editing for sickle cell disease and thalassemia, the evolution of cellular therapy, use of cells, transfusion medicine vs. protein therapy, gene sequencing, immunotherapy, and new targeted drugs.
Includes more decision-making algorithms for formulating diagnoses and personalized treatment plans for those highly complex disorders that require individualized approaches.
Addresses the effects of aging on hematopoiesis and on the manifestations of a variety of hematologic disorders.
Discusses cardio-oncology and its impact on the treatment of patients with hematologic disorders.
Presents relevant basic science as background for clinical application in later sections.
1. Introduction - p. 350 2. Inherited Bone Marrow Failure Syndrome With Multi-Lineage Cytopenias - p. 350 3. Inherited Bone Marrow Failure Syndromes Predominantly with Anemia - p. 375 4. Inherited Bone Marrow Failure Syndromes with Predominantly Neutropenia - p. 386 5. Inherited Bone Marrow Failure Syndromes With Predominantly Thrombocytopenia - p. 393 6. Suggested Readings - p. 394 7. Chapter 31. Aplastic Anemia - p. 396 8. Chapter 32. Paroxysmal Nocturnal Hemoglobinuria - p. 416 9. Chapter 33. Acquired Disorders of Red Cell, White Cell, and Platelet Production - p. 431 10. Abstract - p. 431 11. Etiology and Classification - p. 431 12. Pathogenesis - p. 431 13. Primary Pure Red Cell Aplasia - p. 432 14. Secondary Forms of Pure Red Cell Aplasia - p. 432 15. Laboratory Evaluation - p. 434 16. Medical - p. 435 17. Hematopoietic Stem Cell Transplantation - p. 436 18. Secondary Forms of Neutropenias - p. 438 19. Laboratory Evaluation - p. 440 20. Nutritional Deficiencies - p. 448 21. Suggested Readings - p. 449 22. References - p. 449 23. Part V: Red Blood Cells - p. 451 24. Chapter 34. Pathobiology of the Human Erythrocyte and Its Hemoglobins - p. 451a 25. Chapter 35. Approach to Anemia in the Adult and Child - p. 463 26. Chapter 36. Iron Homeostasis and Its Disorders - p. 473 27. Chapter 37. Disorders of Iron Homeostasis: Iron Deficiency and Overload - p. 483 28. Chapter 38. Anemia of Chronic Inflammation - p. 498 29. Chapter 39. Heme Biosynthesis and Its Disorders: Porphyrias and Sideroblastic Anemias - p. 507 30. Chapter 40. Megaloblastic Anemias - p. 524 31. Abstract - p. 524 32. Cobalamin - p. 524 33. Folates - p. 528 34. Intracellular One-Carbon Metabolism And Cobalamin–Folate Relationships - p. 531 35. Morphologic Expression Of Megaloblastosis - p. 533 36. Neurologic Dysfunction With Cobalamin Deficiency - p. 534 37. Other Effects Of Cobalamin And Folate Deficiency - p. 536 38. Spectrum Of Clinical Presentations With Cobalamin Deficiency - p. 536 39. Biochemical Indicators Of Evolving Deficiency - p. 536 40. Biochemical Evaluation Of Cobalamin And Folate Deficiencies - p. 537 41. Pathogenesis Of Cobalamin Deficiency - p. 540 42. Pathogenesis Of Folate Deficiency - p. 543 43. Megaloblastic Anemia Not Caused By Folate Or Cobalamin Deficiency - p. 547 44. Therapy - p. 547 45. Routine Supplementation Of Cobalamin And Folate - p. 551 46. Future Directions - p. 553 47. Suggested Readings - p. 553 48. References - p. 553 49. Chapter 41. Thalassemia Syndromes - p. 555 50. Abstract - p. 555 51. Definitions And Nomenclature - p. 555 52. Epidemiology - p. 555 53. Pathophysiology: General Principles - p. 555 54. BETA-Thalassemia Syndromes - p. 556 55. ALPHA-Thalassemia Syndromes - p. 579 56. Thalassemic Structural Variants - p. 583 57. Extraordinarily Unstable Hemoglobins - p. 584 58. References - p. 584 59. Suggested Readings - p. 584 60. Chapter 42. Pathobiology of Sickle Cell Disease - p. 585 61. Chapter 43. Clinical Aspects of Sickle Cell Disease - p. 599 62. Abstract - p. 599 63. Genetic Epidemiology of the Sickle Gene - p. 599 64. Variant Sickle Cell Syndromes - p. 599 65. Prevalence - p. 599 66. Clinical Laboratory Features and Diagnosis - p. 600 67. Clinical Presentation and Management - p. 602 68. Suggested Readings - p. 629 69. References - p. 629 70. Chapter 44. Hemoglobin Variants Associated With Hemolytic Anemia, Altered Oxygen Affinity, and Methemoglobinemias - p. 630 71. Chapter 45. Red Blood Cell Enzymopathies - p. 638 72. Chapter 46. Red Blood Cell Membrane Disorders - p. 650 73. Chapter 47. Autoimmune Hemolytic Anemia - p. 672 74. Chapter 48. Extrinsic Nonimmune Hemolytic Anemias - p. 688 75. Part VI: Non-Malignant Leukocytes - p. 698 76. Chapter 49. Neutrophilic Leukocytosis, Neutropenia, Monocytosis, and Monocytopenia - p. 698a 77. Chapter 50. Lymphocytosis, Lymphocytopenia, Hypergammaglobulinemia, and Hypogammaglobulinemia - p. 708 78. Chapter 51. Disorders of Phagocyte Function - p. 717 79. Chapter 52. Congenital Disorders of Lymphocyte Function - p. 736 80. Chapter 53. Pediatric and Adult Histiocytic Disorders - p. 750 81. Chapter 54. Lysosomal Storage Diseases, Focusing On Gaucher Disease: Perspectives And Principles - p. 769 82. Chapter 55. Epstein-Barr Virus and Associated Lymphoproliferative Conditions - p. 782 83. Part VII: Hematologic Malignancies - p. 800 84. Chapter 56. Progress in the Classification of Hematopoietic and Lymphoid Neoplasms: Clinical Implications - p. 800a 85. Chapter 57. Conventional and Molecular Cytogenomic Basis of Hematologic Malignancies - p. 813 86. Abstract - p. 813 87. Methods - p. 813 88. Myelodysplastic Syndromes - p. 833 89. Acute Myeloid Leukemia - p. 842 90. Acute Lymphoblastic Leukemia - p. 863 91. Chronic B-Cell Lymphocytic Leukemia (Chapter 76) - p. 871 92. Multiple Myeloma - p. 877 93. Lymphoma - p. 883 94. Hairy Cell Leukemia (Chapter 77) - p. 891 95. Allogeneic Hematopoietic Stem Cell Transplantation - p. 896 96. Future Directions - p. 897 97. References - p. 898 98. Chapter 58. Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies - p. 900 99. Abstract - p. 900 100. Tumor Cell Heterogeneity of Hematologic Malignancies - p. 900 101. Development of Chemotherapeutic Agents - p. 901 102. Traditional Cytotoxic Antineoplastic Agents Targeting the Cell Cycle and DNA - p. 902 103. Pharmacology of Traditional Chemotherapeutic Agents - p. 904 104. Pharmacology of Targeted Antineoplastic Agents - p. 912 105. Drug Resistance to Chemotherapeutic Agents or Multidrug Resistance - p. 931 106. Future Directions - p. 936 107. SUGGESTED READINGS - p. 936 108. Reference - p. 936 109. Chapter 59. Pathobiology of Acute Myeloid Leukemia - p. 937 110. Chapter 60. Clinical Manifestations and Treatment of Acute Myeloid Leukemia - p. 950 111. Chapter 61. Myelodysplastic Syndromes - p. 977 112. Abstract - p. 977 113. History - p. 977 114. Classification - p. 977 115. Epidemiology - p. 978 116. Pathobiology - p. 980 117. Germline Predisposition - p. 980 118. Clinical Manifestations - p. 985 119. Laboratory Manifestations - p. 986 120. Differential Diagnosis - p. 990 121. Prognosis - p. 991 122. Treatment of Patients with Myelodysplastic Syndromes - p. 993 123. Future Directions - p. 1000 124. Suggested Readings - p. 1000 125. References - p. 1000 126. Chapter 62. Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults - p. 1001 127. Chapter 63. Acute Myeloid Leukemia in Children - p. 1013 128. Chapter 64. Blastic Plasmacytoid Dendritic Cell Neoplasm - p. 1029 129. Chapter 65. Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children - p. 1036 130. Chapter 66. Pathobiology of Acute Lymphoblastic Leukemia - p. 1049 131. Chapter 67. Clinical Manifestations and Treatment of Childhood Acute Lymphoblastic Leukemia - p. 1066 132. Chapter 68. Acute Lymphoblastic Leukemia in Adults - p. 1078 133. Chapter 69. Chronic Myeloid Leukemia - p. 1103 134. Abstract - p. 1103 135. Introduction and Historical Perspective - p. 1103 136. Epidemiology - p. 1105 137. Molecular Biology - p. 1105 138. Cellular Biology - p. 1109 139. Transformation to Accelerated and Blast Phase - p. 1112 140. Molecular Basis of Tyrosine Kinase Inhibitor Resistance - p. 1112 141. Diagnosis and Initial Workup - p. 1115 142. Risk Stratification - p. 1116 143. Differential Diagnosis - p. 1118 144. Monitoring Response to Therapy - p. 1118 145. Therapy - p. 1120 146. Approach to the Newly Diagnosed Chronic Phase Patient - p. 1122 147. Approach to the Patient with Tyrosine Kinase Inhibitor Resistance - p. 1124 148. Treatment-Free Remission - p. 1125 149. Future Directions - p. 1126 150. Acknowledgments - p. 1127 151. Suggested Readings - p. 1127 152. References - p. 1127 153. Chapter 70. The Polycythemias - p. 1129 154. Abstract - p. 1129 155. Erythropoiesis - p. 1129 156. Erythropoietin, Oxygen Sensing, and Hypoxia-Inducible Factor - p. 1129 157. The Erythropoietin Receptor - p. 1131 158. The Renin–Angiotensin System and Hematopoiesis - p. 1131 159. Definition and Classification of Polycythemia - p. 1132 160. Relative Polycythemia - p. 1132 161. Absolute Polycythemias - p. 1133 162. Secondary Polycythemias - p. 1134 163. Polycythemia Vera - p. 1139 164. Clinical Manifestations - p. 1150 165. Laboratory Manifestations - p. 1154 166. Cytogenomic Abnormalities - p. 1156 167. Differential Diagnosis - p. 1158 168. Prognosis - p. 1159 169. Therapy - p. 1160 170. Future Directions - p. 1167 171. Update - p. 1168.e1 172. Suggested Readings - p. 1168.e1 173. References - p. 1168.e1 174. Chapter 71. Essential Thrombocythemia - p. 1169 175. Chapter 72. Primary Myelofibrosis and Chronic Neutrophilic Leukemia - p. 1193 176. Chapter 73. Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes - p. 1225 177. Chapter 74. Eosinophilia, Eosinophilic Neoplasms, and the Hypereosinophilic Syndromes - p. 1243 178. Chapter 75. Mast Cells and Mastocytosis - p. 1263 179. Chapter 76. Chronic Lymphocytic Leukemia - p. 1282 180. Chapter 77. Hairy Cell Leukemia - p. 1301 181. Chapter 78. The Pathologic Basis for the Classification of Non-Hodgkin and Hodgkin Lymphomas - p. 1314 182. Chapter 79. Origin of Hodgkin Lymphoma and Therapeutic Targets - p. 1331 183. Chapter 80. Hodgkin Lymphoma - p. 1339 184. Chapter81. Origin of Non-Hodgkin Lymphoma and Therapeutic Targets - p. 1352 185. Chapter 82. Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma - p. 1367 186. Chapter 83. Marginal Zone Lymphomas (Extranodal/Malt, Splenic, and Nodal) - p. 1378 187. Chapter 84. Diffuse Large B-Cell Lymphoma of the Central Nervous System - p. 1390 188. Epidemiology - p. 1390 189. Pathogenesis - p. 1390 190. Clinical Presentation - p. 1394 191. Neuroimaging - p. 1394 192. Neuroimaging and Differential Diagnosis Prior to Biopsy - p. 1395 193. Tissue Diagnosis - p. 1396 194. Cerebrospinal Fluid Assessment for Diagnosis - p. 1396 195. Ophthalmology Exam and Vitreoretinal Specimen Testing for Diagnosis - p. 1397 196. Histology Characterization - p. 1398 197. Biomarkers for Diagnosis - p. 1399 198. Staging - p. 1400 199. Frontline Therapy and Response Assessment - p. 1401 200. Induction Therapy - p. 1401 201. Consolidation - p. 1402 202. Primary Central Nervous System Lymphoma in Older Adults - p. 1405 203. Induction in Older Adults—Should it Be REDUCED? - p. 1405 204. AUTOLOGOUS Hematopoietic Stem Cell Transplantation in Older Adults as Consolidation Therapy - p. 1406 205. Maintenance Therapy—Emerging Concept - p. 1406 206. Treatment of Primary Vitreoretinal Lymphoma - A Subset of Primary Central Nervous System Lymphoma - p. 1407 207. Real-World Treatment Patterns and Outcomes—Data from Population-Based Studies - p. 1407 208. Primary Central Nervous System Lymphoma in the Immunocompromised Host - p. 1408 209. Post-Transplant Lymphoproliferative Disease–Related Primary Central Nervous System Lymphoma - p. 1409 210. Autoimmune Disease–Related Primary Central Nervous System Lymphoma - p. 1409 211. Experimental Therapeutics in Primary Central Nervous System Lymphoma - p. 1409 212. NGR-Human Tumor Necrosis Factor With R-CHOP - p. 1409 213. Front-line Treatment Challenges and Controversies - p. 1410 214. Prognostic and Predictive Markers - p. 1412 215. Additional Prognostic and Predictive Markers - p. 1413 216. Relapsed and Refractory Disease - p. 1414 217. Non-Chemotherapeutic Targets and Agents - p. 1414 218. Prevention of Cns Relapse for Aggressive Systemic Lymphomas and Controversies - p. 1417 219. Perspective and Future Directions - p. 1417 220. Acknowledgments - p. 1417 221. Suggested Readings - p. 1417 222. References - p. 1417 223. Chapter 85. High-Grade B-Cell Lymphomas - p. 1420 224. Chapter 86. Mantle Cell Lymphoma - p. 1430 225. Chapter 87. Virus-Associated Lymphoma - p. 1439 226. Chapter 88. Malignant Lymphomas in Childhood - p. 1448 227. Chapter 89. T-Cell Lymphomas - p. 1462 228. Chapter 90. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma - p. 1492 229. Chapter 91. Multiple Myeloma - p. 1506 230. Abstract - p. 1506 231. Screening, Epidemiology, and Risk Factors - p. 1506 232. Pathogenesis - p. 1506 233. Clinical Implications of Clonal Heterogeneity and Evolution - p. 1510222 234. Immune and Bone Marrow Microenvironment - p. 1510222 235. Clinical Manifestations - p. 1512 236. Genomic Biomarkers - p. 1524 237. Differential Diagnosis - p. 1524 238. Indications for Treatment - p. 1524 239. Treatment of Newly Diagnosed Myeloma - p. 1526 240. Relapsed Disease - p. 1533 241. Future Directions - p. 1538 242. Update - p. 1538.e2 243. Update - p. 1538.e2 244. Update - p. 1538.e3 245. Suggested Readings - p. 1538.e4 246. References - p. 1538.e4 247. Chapter 92. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma - p. 1539 248. Chapter 93. Immunoglobulin Light-Chain Amyloidosis (Primary Amyloidosis) - p. 1553 249. Part VIII: Comprehensive Care of Patients with Hematologic Malignancies - p. 1567 250. Chapter 94. Key Considerations for Managing Infections in the Compromised Host - p. 1567a 251. Chapter 95. Principles of Radiation Therapy for Hematologic Disease - p. 1583 252. Chapter 96. Grading and Toxicity Management after Immune Effector Therapy - p. 1594 253. Chapter 97. Identification and Management of Checkpoint Inhibition Toxicity - p. 1599 254. Chapter 98. Psychosocial Aspects Of Hematologic Disorders - p. 1605 255. Chapter 99. Pain Management and Antiemetic Therapy in Hematologic Disorders - p. 1616 256. Chapter 100. Palliative Care - p. 1631 257. Chapter 101. Therapy-Related Late Effects of Hematologic Malignancies - p. 1638 258. Part IX: Transplantation and Other Cell-Based Therapies - p. 1653 259. Chapter 102. Practical Aspects of Hematopoietic Stem Cell Harvesting and Mobilization - p. 1653a 260. Chapter 103. Graft Engineering and Cell Processing - p. 1667 261. Chapter 104. Principles of Cell-Based Genetic Therapies - p. 1679 262. Chapter 105. Indications, Outcomes, and Donor Selection for Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults - p. 1689 263. Chapter 106. Unrelated Donor Hematopoietic Cell Transplantation - p. 1703 264. Chapter 107. Haploidentical Hematopoietic Stem Cell Transplantation - p. 1713 265. Chapter 108. Cord Blood Transplantation - p. 1732 266. Chapter 109. Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses - p. 1749 267. Chapter 110. Supportive Care for the Transplant Patient - p. 1770 268. Part X: Transfusion Medicine - p. 1785 269. Chapter 111. Human Blood Group Antigens and Antibodies - p. 1785a 270. Chapter 112. Principles of Red Blood Cell Transfusion - p. 1801 271. Chapter 113. Clinical Considerations in Platelet Transfusion Therapy - p. 1814 272. Chapter 114. Human Leukocyte Antigen and Human Neutrophil Antigen Systems - p. 1820 273. Chapter 115. Principles Of Plasma And Plasma Derivatives - p. 1837 274. Chapter 116. Hemapheresis - p. 1852 275. Chapter 117. Transfusion Reactions to Blood and Hematopoietic Stem Cell Therapy Products - p. 1864 276. Chapter 118. Transfusion-Transmitted Diseases - p. 1874 277. Chapter 119. Pediatric Transfusion Medicine - p. 1892 278. Chapter 120. Transfusion and Apheresis Support for Sickle Cell Disease Patients - p. 1900 279. Part XI: Hemostasis and Thrombosis - p. 1906 280. Chapter 121. Overview of Hemostasis and Thrombosis - p. 1906a 281. Chapter 122. Blood Vessels - p. 1919 282. Chapter 123. Megakaryocyte And Platelet Structure - p. 1937 283. Chapter 124. Molecular Basis of Platelet Function - p. 1950 284. Chapter 125. Molecular Basis of Blood Coagulation - p. 1968 285. Chapter 126. Evaluation of the Patient With Suspected Bleeding Disorders - p. 1988 286. Chapter 127. Laboratory Evaluation of Hemostatic and Thrombotic Disorders - p. 1996 287. Chapter 128. Acquired Disorders of Platelet Function - p. 2007 288. Chapter 129. Diseases of Platelet Number: Immune Thrombocytopenia, Neonatal Alloimmune Thrombocytopenia, and Posttransfusion Purpura - p. 2020 289. Chapter 130. Thrombocytopenia Caused by Hypersplenism, Platelet Destruction, or Surgery/Hemodilution - p. 2033 290. Chapter 131. Heparin-Induced Thrombocytopenia - p. 2049 291. Chapter 132. Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndromes - p. 2063 292. Chapter 133. Structure, Biology, and Genetics of von Willebrand Factor - p. 2081 293. Chapter 134. Hemophilia A and B - p. 2095 294. Abstract - p. 2095 295. Epidemiology - p. 2095 296. Factor VIII Biology: Genetics, Structure, Function, and Pathophysiology - p. 2096 297. Pathophysiology of Hemophilia A - p. 2098 298. Factor Ix Biology: Genetics, Structure, Function, and Pathophysiology - p. 2099 299. Clinical Features of Hemophilia - p. 2103 300. Clinical Management of Hemophilia - p. 2107 301. Inhibitors in Hemophilia B - p. 2120 302. Management of Inhibitors in Hemophilia B - p. 2121 303. Gene Therapy for Hemophilia - p. 2121 304. Hemophilia in the World—Economic Considerations - p. 2123 305. Acknowledgment - p. 2124 306. Update - p. 2124.e1 307. Update - p. 2124.e1 308. Suggested Readings - p. 2124.e2 309. References - p. 2124.e2 310. Chapter 135. Rare Coagulation Factor Deficiencies - p. 2125 311. Chapter 136. Transfusion Therapy for Coagulation Factor Deficiencies - p. 2144 312. Chapter 137. Disseminated Intravascular Coagulation - p. 2156 313. Chapter 138. Hypercoagulable States - p. 2167 314. Chapter 139. Antiphospholipid Syndrome - p. 2179 315. Chapter 140. Venous Thromboembolism - p. 2196 316. Chapter 141. Prevention and Treatment of Venous Thromboembolism in Pregnancy - p. 2205 317. Chapter 142. Atherothrombosis - p. 2212 318. Chapter 143. Antithrombotic Drugs - p. 2223 319. Chapter 144. Stroke - p. 2241 320. Chapter 145. Acute Coronary Syndromes - p. 2251 321. Chapter 146. Peripheral Artery Disease - p. 2261 322. Chapter 147. Atrial Fibrillation - p. 2270 323. Chapter 148. Bleeding And Clotting Disorders In Pediatrics - p. 2278 324. Part XII: Consultative Hematology - p. 2292 325. Chapter 149. Hematologic Changes in Pregnancy - p. 2292a 326. Chapter 150. Hematologic Manifestations of End-Organ Failure - p. 2305 327. Chapter 151. Hematologic Manifestations of Solid Tumors - p. 2312 328. Chapter 152. Hematologic Manifestations of HIV/AIDS - p. 2319 329. Chapter 153. Hematologic Findings And Consequences Of Novel Coronavirus (SARS-COV-2) Infection - p. 2335 330. Chapter 154. Hematologic Aspects of Parasitic Diseases - p. 2342 331. Abstract - p. 2342 332. Malaria - p. 2342 333. Visceral Leishmaniasis - p. 2353 334. African Trypanosomiasis - p. 2356 335. American Trypanosomiasis - p. 2360 336. Babesiosis - p. 2363 337. Eosinophilia - p. 2365 338. Other Parasitic Diseases - p. 2366 339. Future Directions - p. 2367 340. Suggested Readings - p. 2367 341. References - p. 2367 342. Chapter 155. Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis - p. 2369 343. Chapter 156. The Spleen and Its Disorders - p. 2378 344. Chapter 157. Aging and Hematologic Disorders - p. 2394 345. Chapter 158. Onco-Cardiology: Focus on Cardiac Complications of Hematologic Treatments - p. 2400 346. Chapter 159. Resources for the Hematologist: Interpretive Comments and Selected Reference Values for Neonatal, Pediatric, and Adult Populations - p. 2408.e3 347. Index - p. 2409 348. Confidence is ClinicalKey - p. 2476
Extensively revised, comprehensive content from leading global contributors ensures that Hematology, 8th Edition, remains your #1 choice for expert guidance in all areas of this rapidly advancing subspecialty. This edition reflects the numerous advances that are redefining the field and dramatically influencing new approaches to diagnosis, treatment, and outcomes. Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy—covering virtually all aspects of hematology in one definitive resource.
Covers all hematologic disorders, including comprehensive discussions of hematologic malignancies, individualized patient care, cell-based therapies, transplantation, transfusion medicine, hemostasis, thrombosis, and consultative hematology—in one convenient volume.
Provides state-of-the-art guidance from global experts at the forefront of the latest research and clinical practice.
Provides extensive updates throughout on basic science research, advances in molecular diagnostics, new drugs, immunotherapies, personalized medicine, laboratory medicine, transfusion medicine, stem cell transplantation, and clinical treatment for all hematologic malignancies and non-malignancies
Contains new chapters on gene editing; the impact of mitochondria on hematopoiesis; myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes; immunotherapy and management of its toxicities; transfusion medicine in sickle cell disease; principles of radiation therapy; and COVID-19, including complications of vaccination and its impact on the hematologic system.
Discusses many new advances in the field, including details and the future of gene therapy for hemophilia, gene editing for sickle cell disease and thalassemia, the evolution of cellular therapy, use of cells, transfusion medicine vs. protein therapy, gene sequencing, immunotherapy, and new targeted drugs.
Includes more decision-making algorithms for formulating diagnoses and personalized treatment plans for those highly complex disorders that require individualized approaches.
Addresses the effects of aging on hematopoiesis and on the manifestations of a variety of hematologic disorders.
Discusses cardio-oncology and its impact on the treatment of patients with hematologic disorders.
Presents relevant basic science as background for clinical application in later sections.
1. Introduction - p. 350 2. Inherited Bone Marrow Failure Syndrome With Multi-Lineage Cytopenias - p. 350 3. Inherited Bone Marrow Failure Syndromes Predominantly with Anemia - p. 375 4. Inherited Bone Marrow Failure Syndromes with Predominantly Neutropenia - p. 386 5. Inherited Bone Marrow Failure Syndromes With Predominantly Thrombocytopenia - p. 393 6. Suggested Readings - p. 394 7. Chapter 31. Aplastic Anemia - p. 396 8. Chapter 32. Paroxysmal Nocturnal Hemoglobinuria - p. 416 9. Chapter 33. Acquired Disorders of Red Cell, White Cell, and Platelet Production - p. 431 10. Abstract - p. 431 11. Etiology and Classification - p. 431 12. Pathogenesis - p. 431 13. Primary Pure Red Cell Aplasia - p. 432 14. Secondary Forms of Pure Red Cell Aplasia - p. 432 15. Laboratory Evaluation - p. 434 16. Medical - p. 435 17. Hematopoietic Stem Cell Transplantation - p. 436 18. Secondary Forms of Neutropenias - p. 438 19. Laboratory Evaluation - p. 440 20. Nutritional Deficiencies - p. 448 21. Suggested Readings - p. 449 22. References - p. 449 23. Part V: Red Blood Cells - p. 451 24. Chapter 34. Pathobiology of the Human Erythrocyte and Its Hemoglobins - p. 451a 25. Chapter 35. Approach to Anemia in the Adult and Child - p. 463 26. Chapter 36. Iron Homeostasis and Its Disorders - p. 473 27. Chapter 37. Disorders of Iron Homeostasis: Iron Deficiency and Overload - p. 483 28. Chapter 38. Anemia of Chronic Inflammation - p. 498 29. Chapter 39. Heme Biosynthesis and Its Disorders: Porphyrias and Sideroblastic Anemias - p. 507 30. Chapter 40. Megaloblastic Anemias - p. 524 31. Abstract - p. 524 32. Cobalamin - p. 524 33. Folates - p. 528 34. Intracellular One-Carbon Metabolism And Cobalamin–Folate Relationships - p. 531 35. Morphologic Expression Of Megaloblastosis - p. 533 36. Neurologic Dysfunction With Cobalamin Deficiency - p. 534 37. Other Effects Of Cobalamin And Folate Deficiency - p. 536 38. Spectrum Of Clinical Presentations With Cobalamin Deficiency - p. 536 39. Biochemical Indicators Of Evolving Deficiency - p. 536 40. Biochemical Evaluation Of Cobalamin And Folate Deficiencies - p. 537 41. Pathogenesis Of Cobalamin Deficiency - p. 540 42. Pathogenesis Of Folate Deficiency - p. 543 43. Megaloblastic Anemia Not Caused By Folate Or Cobalamin Deficiency - p. 547 44. Therapy - p. 547 45. Routine Supplementation Of Cobalamin And Folate - p. 551 46. Future Directions - p. 553 47. Suggested Readings - p. 553 48. References - p. 553 49. Chapter 41. Thalassemia Syndromes - p. 555 50. Abstract - p. 555 51. Definitions And Nomenclature - p. 555 52. Epidemiology - p. 555 53. Pathophysiology: General Principles - p. 555 54. BETA-Thalassemia Syndromes - p. 556 55. ALPHA-Thalassemia Syndromes - p. 579 56. Thalassemic Structural Variants - p. 583 57. Extraordinarily Unstable Hemoglobins - p. 584 58. References - p. 584 59. Suggested Readings - p. 584 60. Chapter 42. Pathobiology of Sickle Cell Disease - p. 585 61. Chapter 43. Clinical Aspects of Sickle Cell Disease - p. 599 62. Abstract - p. 599 63. Genetic Epidemiology of the Sickle Gene - p. 599 64. Variant Sickle Cell Syndromes - p. 599 65. Prevalence - p. 599 66. Clinical Laboratory Features and Diagnosis - p. 600 67. Clinical Presentation and Management - p. 602 68. Suggested Readings - p. 629 69. References - p. 629 70. Chapter 44. Hemoglobin Variants Associated With Hemolytic Anemia, Altered Oxygen Affinity, and Methemoglobinemias - p. 630 71. Chapter 45. Red Blood Cell Enzymopathies - p. 638 72. Chapter 46. Red Blood Cell Membrane Disorders - p. 650 73. Chapter 47. Autoimmune Hemolytic Anemia - p. 672 74. Chapter 48. Extrinsic Nonimmune Hemolytic Anemias - p. 688 75. Part VI: Non-Malignant Leukocytes - p. 698 76. Chapter 49. Neutrophilic Leukocytosis, Neutropenia, Monocytosis, and Monocytopenia - p. 698a 77. Chapter 50. Lymphocytosis, Lymphocytopenia, Hypergammaglobulinemia, and Hypogammaglobulinemia - p. 708 78. Chapter 51. Disorders of Phagocyte Function - p. 717 79. Chapter 52. Congenital Disorders of Lymphocyte Function - p. 736 80. Chapter 53. Pediatric and Adult Histiocytic Disorders - p. 750 81. Chapter 54. Lysosomal Storage Diseases, Focusing On Gaucher Disease: Perspectives And Principles - p. 769 82. Chapter 55. Epstein-Barr Virus and Associated Lymphoproliferative Conditions - p. 782 83. Part VII: Hematologic Malignancies - p. 800 84. Chapter 56. Progress in the Classification of Hematopoietic and Lymphoid Neoplasms: Clinical Implications - p. 800a 85. Chapter 57. Conventional and Molecular Cytogenomic Basis of Hematologic Malignancies - p. 813 86. Abstract - p. 813 87. Methods - p. 813 88. Myelodysplastic Syndromes - p. 833 89. Acute Myeloid Leukemia - p. 842 90. Acute Lymphoblastic Leukemia - p. 863 91. Chronic B-Cell Lymphocytic Leukemia (Chapter 76) - p. 871 92. Multiple Myeloma - p. 877 93. Lymphoma - p. 883 94. Hairy Cell Leukemia (Chapter 77) - p. 891 95. Allogeneic Hematopoietic Stem Cell Transplantation - p. 896 96. Future Directions - p. 897 97. References - p. 898 98. Chapter 58. Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies - p. 900 99. Abstract - p. 900 100. Tumor Cell Heterogeneity of Hematologic Malignancies - p. 900 101. Development of Chemotherapeutic Agents - p. 901 102. Traditional Cytotoxic Antineoplastic Agents Targeting the Cell Cycle and DNA - p. 902 103. Pharmacology of Traditional Chemotherapeutic Agents - p. 904 104. Pharmacology of Targeted Antineoplastic Agents - p. 912 105. Drug Resistance to Chemotherapeutic Agents or Multidrug Resistance - p. 931 106. Future Directions - p. 936 107. SUGGESTED READINGS - p. 936 108. Reference - p. 936 109. Chapter 59. Pathobiology of Acute Myeloid Leukemia - p. 937 110. Chapter 60. Clinical Manifestations and Treatment of Acute Myeloid Leukemia - p. 950 111. Chapter 61. Myelodysplastic Syndromes - p. 977 112. Abstract - p. 977 113. History - p. 977 114. Classification - p. 977 115. Epidemiology - p. 978 116. Pathobiology - p. 980 117. Germline Predisposition - p. 980 118. Clinical Manifestations - p. 985 119. Laboratory Manifestations - p. 986 120. Differential Diagnosis - p. 990 121. Prognosis - p. 991 122. Treatment of Patients with Myelodysplastic Syndromes - p. 993 123. Future Directions - p. 1000 124. Suggested Readings - p. 1000 125. References - p. 1000 126. Chapter 62. Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome in Adults - p. 1001 127. Chapter 63. Acute Myeloid Leukemia in Children - p. 1013 128. Chapter 64. Blastic Plasmacytoid Dendritic Cell Neoplasm - p. 1029 129. Chapter 65. Myelodysplastic Syndromes and Myeloproliferative Neoplasms in Children - p. 1036 130. Chapter 66. Pathobiology of Acute Lymphoblastic Leukemia - p. 1049 131. Chapter 67. Clinical Manifestations and Treatment of Childhood Acute Lymphoblastic Leukemia - p. 1066 132. Chapter 68. Acute Lymphoblastic Leukemia in Adults - p. 1078 133. Chapter 69. Chronic Myeloid Leukemia - p. 1103 134. Abstract - p. 1103 135. Introduction and Historical Perspective - p. 1103 136. Epidemiology - p. 1105 137. Molecular Biology - p. 1105 138. Cellular Biology - p. 1109 139. Transformation to Accelerated and Blast Phase - p. 1112 140. Molecular Basis of Tyrosine Kinase Inhibitor Resistance - p. 1112 141. Diagnosis and Initial Workup - p. 1115 142. Risk Stratification - p. 1116 143. Differential Diagnosis - p. 1118 144. Monitoring Response to Therapy - p. 1118 145. Therapy - p. 1120 146. Approach to the Newly Diagnosed Chronic Phase Patient - p. 1122 147. Approach to the Patient with Tyrosine Kinase Inhibitor Resistance - p. 1124 148. Treatment-Free Remission - p. 1125 149. Future Directions - p. 1126 150. Acknowledgments - p. 1127 151. Suggested Readings - p. 1127 152. References - p. 1127 153. Chapter 70. The Polycythemias - p. 1129 154. Abstract - p. 1129 155. Erythropoiesis - p. 1129 156. Erythropoietin, Oxygen Sensing, and Hypoxia-Inducible Factor - p. 1129 157. The Erythropoietin Receptor - p. 1131 158. The Renin–Angiotensin System and Hematopoiesis - p. 1131 159. Definition and Classification of Polycythemia - p. 1132 160. Relative Polycythemia - p. 1132 161. Absolute Polycythemias - p. 1133 162. Secondary Polycythemias - p. 1134 163. Polycythemia Vera - p. 1139 164. Clinical Manifestations - p. 1150 165. Laboratory Manifestations - p. 1154 166. Cytogenomic Abnormalities - p. 1156 167. Differential Diagnosis - p. 1158 168. Prognosis - p. 1159 169. Therapy - p. 1160 170. Future Directions - p. 1167 171. Update - p. 1168.e1 172. Suggested Readings - p. 1168.e1 173. References - p. 1168.e1 174. Chapter 71. Essential Thrombocythemia - p. 1169 175. Chapter 72. Primary Myelofibrosis and Chronic Neutrophilic Leukemia - p. 1193 176. Chapter 73. Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes - p. 1225 177. Chapter 74. Eosinophilia, Eosinophilic Neoplasms, and the Hypereosinophilic Syndromes - p. 1243 178. Chapter 75. Mast Cells and Mastocytosis - p. 1263 179. Chapter 76. Chronic Lymphocytic Leukemia - p. 1282 180. Chapter 77. Hairy Cell Leukemia - p. 1301 181. Chapter 78. The Pathologic Basis for the Classification of Non-Hodgkin and Hodgkin Lymphomas - p. 1314 182. Chapter 79. Origin of Hodgkin Lymphoma and Therapeutic Targets - p. 1331 183. Chapter 80. Hodgkin Lymphoma - p. 1339 184. Chapter81. Origin of Non-Hodgkin Lymphoma and Therapeutic Targets - p. 1352 185. Chapter 82. Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma - p. 1367 186. Chapter 83. Marginal Zone Lymphomas (Extranodal/Malt, Splenic, and Nodal) - p. 1378 187. Chapter 84. Diffuse Large B-Cell Lymphoma of the Central Nervous System - p. 1390 188. Epidemiology - p. 1390 189. Pathogenesis - p. 1390 190. Clinical Presentation - p. 1394 191. Neuroimaging - p. 1394 192. Neuroimaging and Differential Diagnosis Prior to Biopsy - p. 1395 193. Tissue Diagnosis - p. 1396 194. Cerebrospinal Fluid Assessment for Diagnosis - p. 1396 195. Ophthalmology Exam and Vitreoretinal Specimen Testing for Diagnosis - p. 1397 196. Histology Characterization - p. 1398 197. Biomarkers for Diagnosis - p. 1399 198. Staging - p. 1400 199. Frontline Therapy and Response Assessment - p. 1401 200. Induction Therapy - p. 1401 201. Consolidation - p. 1402 202. Primary Central Nervous System Lymphoma in Older Adults - p. 1405 203. Induction in Older Adults—Should it Be REDUCED? - p. 1405 204. AUTOLOGOUS Hematopoietic Stem Cell Transplantation in Older Adults as Consolidation Therapy - p. 1406 205. Maintenance Therapy—Emerging Concept - p. 1406 206. Treatment of Primary Vitreoretinal Lymphoma - A Subset of Primary Central Nervous System Lymphoma - p. 1407 207. Real-World Treatment Patterns and Outcomes—Data from Population-Based Studies - p. 1407 208. Primary Central Nervous System Lymphoma in the Immunocompromised Host - p. 1408 209. Post-Transplant Lymphoproliferative Disease–Related Primary Central Nervous System Lymphoma - p. 1409 210. Autoimmune Disease–Related Primary Central Nervous System Lymphoma - p. 1409 211. Experimental Therapeutics in Primary Central Nervous System Lymphoma - p. 1409 212. NGR-Human Tumor Necrosis Factor With R-CHOP - p. 1409 213. Front-line Treatment Challenges and Controversies - p. 1410 214. Prognostic and Predictive Markers - p. 1412 215. Additional Prognostic and Predictive Markers - p. 1413 216. Relapsed and Refractory Disease - p. 1414 217. Non-Chemotherapeutic Targets and Agents - p. 1414 218. Prevention of Cns Relapse for Aggressive Systemic Lymphomas and Controversies - p. 1417 219. Perspective and Future Directions - p. 1417 220. Acknowledgments - p. 1417 221. Suggested Readings - p. 1417 222. References - p. 1417 223. Chapter 85. High-Grade B-Cell Lymphomas - p. 1420 224. Chapter 86. Mantle Cell Lymphoma - p. 1430 225. Chapter 87. Virus-Associated Lymphoma - p. 1439 226. Chapter 88. Malignant Lymphomas in Childhood - p. 1448 227. Chapter 89. T-Cell Lymphomas - p. 1462 228. Chapter 90. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma - p. 1492 229. Chapter 91. Multiple Myeloma - p. 1506 230. Abstract - p. 1506 231. Screening, Epidemiology, and Risk Factors - p. 1506 232. Pathogenesis - p. 1506 233. Clinical Implications of Clonal Heterogeneity and Evolution - p. 1510222 234. Immune and Bone Marrow Microenvironment - p. 1510222 235. Clinical Manifestations - p. 1512 236. Genomic Biomarkers - p. 1524 237. Differential Diagnosis - p. 1524 238. Indications for Treatment - p. 1524 239. Treatment of Newly Diagnosed Myeloma - p. 1526 240. Relapsed Disease - p. 1533 241. Future Directions - p. 1538 242. Update - p. 1538.e2 243. Update - p. 1538.e2 244. Update - p. 1538.e3 245. Suggested Readings - p. 1538.e4 246. References - p. 1538.e4 247. Chapter 92. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma - p. 1539 248. Chapter 93. Immunoglobulin Light-Chain Amyloidosis (Primary Amyloidosis) - p. 1553 249. Part VIII: Comprehensive Care of Patients with Hematologic Malignancies - p. 1567 250. Chapter 94. Key Considerations for Managing Infections in the Compromised Host - p. 1567a 251. Chapter 95. Principles of Radiation Therapy for Hematologic Disease - p. 1583 252. Chapter 96. Grading and Toxicity Management after Immune Effector Therapy - p. 1594 253. Chapter 97. Identification and Management of Checkpoint Inhibition Toxicity - p. 1599 254. Chapter 98. Psychosocial Aspects Of Hematologic Disorders - p. 1605 255. Chapter 99. Pain Management and Antiemetic Therapy in Hematologic Disorders - p. 1616 256. Chapter 100. Palliative Care - p. 1631 257. Chapter 101. Therapy-Related Late Effects of Hematologic Malignancies - p. 1638 258. Part IX: Transplantation and Other Cell-Based Therapies - p. 1653 259. Chapter 102. Practical Aspects of Hematopoietic Stem Cell Harvesting and Mobilization - p. 1653a 260. Chapter 103. Graft Engineering and Cell Processing - p. 1667 261. Chapter 104. Principles of Cell-Based Genetic Therapies - p. 1679 262. Chapter 105. Indications, Outcomes, and Donor Selection for Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults - p. 1689 263. Chapter 106. Unrelated Donor Hematopoietic Cell Transplantation - p. 1703 264. Chapter 107. Haploidentical Hematopoietic Stem Cell Transplantation - p. 1713 265. Chapter 108. Cord Blood Transplantation - p. 1732 266. Chapter 109. Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses - p. 1749 267. Chapter 110. Supportive Care for the Transplant Patient - p. 1770 268. Part X: Transfusion Medicine - p. 1785 269. Chapter 111. Human Blood Group Antigens and Antibodies - p. 1785a 270. Chapter 112. Principles of Red Blood Cell Transfusion - p. 1801 271. Chapter 113. Clinical Considerations in Platelet Transfusion Therapy - p. 1814 272. Chapter 114. Human Leukocyte Antigen and Human Neutrophil Antigen Systems - p. 1820 273. Chapter 115. Principles Of Plasma And Plasma Derivatives - p. 1837 274. Chapter 116. Hemapheresis - p. 1852 275. Chapter 117. Transfusion Reactions to Blood and Hematopoietic Stem Cell Therapy Products - p. 1864 276. Chapter 118. Transfusion-Transmitted Diseases - p. 1874 277. Chapter 119. Pediatric Transfusion Medicine - p. 1892 278. Chapter 120. Transfusion and Apheresis Support for Sickle Cell Disease Patients - p. 1900 279. Part XI: Hemostasis and Thrombosis - p. 1906 280. Chapter 121. Overview of Hemostasis and Thrombosis - p. 1906a 281. Chapter 122. Blood Vessels - p. 1919 282. Chapter 123. Megakaryocyte And Platelet Structure - p. 1937 283. Chapter 124. Molecular Basis of Platelet Function - p. 1950 284. Chapter 125. Molecular Basis of Blood Coagulation - p. 1968 285. Chapter 126. Evaluation of the Patient With Suspected Bleeding Disorders - p. 1988 286. Chapter 127. Laboratory Evaluation of Hemostatic and Thrombotic Disorders - p. 1996 287. Chapter 128. Acquired Disorders of Platelet Function - p. 2007 288. Chapter 129. Diseases of Platelet Number: Immune Thrombocytopenia, Neonatal Alloimmune Thrombocytopenia, and Posttransfusion Purpura - p. 2020 289. Chapter 130. Thrombocytopenia Caused by Hypersplenism, Platelet Destruction, or Surgery/Hemodilution - p. 2033 290. Chapter 131. Heparin-Induced Thrombocytopenia - p. 2049 291. Chapter 132. Thrombotic Thrombocytopenic Purpura and the Hemolytic Uremic Syndromes - p. 2063 292. Chapter 133. Structure, Biology, and Genetics of von Willebrand Factor - p. 2081 293. Chapter 134. Hemophilia A and B - p. 2095 294. Abstract - p. 2095 295. Epidemiology - p. 2095 296. Factor VIII Biology: Genetics, Structure, Function, and Pathophysiology - p. 2096 297. Pathophysiology of Hemophilia A - p. 2098 298. Factor Ix Biology: Genetics, Structure, Function, and Pathophysiology - p. 2099 299. Clinical Features of Hemophilia - p. 2103 300. Clinical Management of Hemophilia - p. 2107 301. Inhibitors in Hemophilia B - p. 2120 302. Management of Inhibitors in Hemophilia B - p. 2121 303. Gene Therapy for Hemophilia - p. 2121 304. Hemophilia in the World—Economic Considerations - p. 2123 305. Acknowledgment - p. 2124 306. Update - p. 2124.e1 307. Update - p. 2124.e1 308. Suggested Readings - p. 2124.e2 309. References - p. 2124.e2 310. Chapter 135. Rare Coagulation Factor Deficiencies - p. 2125 311. Chapter 136. Transfusion Therapy for Coagulation Factor Deficiencies - p. 2144 312. Chapter 137. Disseminated Intravascular Coagulation - p. 2156 313. Chapter 138. Hypercoagulable States - p. 2167 314. Chapter 139. Antiphospholipid Syndrome - p. 2179 315. Chapter 140. Venous Thromboembolism - p. 2196 316. Chapter 141. Prevention and Treatment of Venous Thromboembolism in Pregnancy - p. 2205 317. Chapter 142. Atherothrombosis - p. 2212 318. Chapter 143. Antithrombotic Drugs - p. 2223 319. Chapter 144. Stroke - p. 2241 320. Chapter 145. Acute Coronary Syndromes - p. 2251 321. Chapter 146. Peripheral Artery Disease - p. 2261 322. Chapter 147. Atrial Fibrillation - p. 2270 323. Chapter 148. Bleeding And Clotting Disorders In Pediatrics - p. 2278 324. Part XII: Consultative Hematology - p. 2292 325. Chapter 149. Hematologic Changes in Pregnancy - p. 2292a 326. Chapter 150. Hematologic Manifestations of End-Organ Failure - p. 2305 327. Chapter 151. Hematologic Manifestations of Solid Tumors - p. 2312 328. Chapter 152. Hematologic Manifestations of HIV/AIDS - p. 2319 329. Chapter 153. Hematologic Findings And Consequences Of Novel Coronavirus (SARS-COV-2) Infection - p. 2335 330. Chapter 154. Hematologic Aspects of Parasitic Diseases - p. 2342 331. Abstract - p. 2342 332. Malaria - p. 2342 333. Visceral Leishmaniasis - p. 2353 334. African Trypanosomiasis - p. 2356 335. American Trypanosomiasis - p. 2360 336. Babesiosis - p. 2363 337. Eosinophilia - p. 2365 338. Other Parasitic Diseases - p. 2366 339. Future Directions - p. 2367 340. Suggested Readings - p. 2367 341. References - p. 2367 342. Chapter 155. Hematologic Problems in the Surgical Patient: Bleeding and Thrombosis - p. 2369 343. Chapter 156. The Spleen and Its Disorders - p. 2378 344. Chapter 157. Aging and Hematologic Disorders - p. 2394 345. Chapter 158. Onco-Cardiology: Focus on Cardiac Complications of Hematologic Treatments - p. 2400 346. Chapter 159. Resources for the Hematologist: Interpretive Comments and Selected Reference Values for Neonatal, Pediatric, and Adult Populations - p. 2408.e3 347. Index - p. 2409 348. Confidence is ClinicalKey - p. 2476
